William Blair Investment Manageme recently announced the acquisition of new stake in Inhibikase Therapeutics Inc. (NASDAQ:IKT). The institutional investor has increased its shareholding in the Healthcare company by 616.00% to 0.18 million shares with purchase of 0.15 million shares. This fresh investment now brings its stake to 0.71% valued currently at $89500.0.
With over 0.15 million Inhibikase Therapeutics Inc. (IKT) shares trading Monday and a closing price of $0.75 on the day, the dollar volume was approximately $0.11 million. The shares have shown a negative half year performance of -17.54% and its price on 01/23/23 gained nearly 10.32%. Currently, there are 25.23M common shares owned by the public and among those 19.85M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for IKT have a consensus price objective of $6.00. The analysts have set the share’s price value over the next 12 months at a high of $6.00 and a low of $6.00. But an upside of 87.5% will see the stock hit the forecast high price target while median target price for the stock is $6.00.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 18,948 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Inhibikase Therapeutics Inc. are Vanguard Total Stock Market Index, Fidelity Extended Market Index Fu, and Vanguard Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.48 million shares of the company’s stock, all valued at over $0.24 million. Vanguard Extended Market Index Fu bought 178.0 shares to bring its total holdings to over 34539.0 shares at a value of $17270.0. Vanguard Extended Market Index Fu now owns shares totaling to 0.14% of the shares outstanding.
Shares of Inhibikase Therapeutics Inc. (NASDAQ: IKT) opened at $0.70, up $0.02 from a prior closing price of $0.68. However, the script later moved the day high at 0.7880, up 10.32%. The company’s stock has a 5-day price change of 25.05% and -11.22% over the past three months. IKT shares are trading 50.06% year to date (YTD), with the 12-month market performance down to -47.53% lower. It has a 12-month low price of $0.44 and touched a high of $1.52 over the same period. IKT has an average intraday trading volume of 108.04K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 32.87%, 32.19%, and -8.39% respectively.
Institutional ownership of Inhibikase Therapeutics Inc. (NASDAQ: IKT) shares accounts for 18.30% of the company’s 25.23M shares outstanding. Mutual fund holders own 2.57%, while other institutional holders and individual stakeholders account for 21.34% and 15.03% respectively.
It has a market capitalization of $18.20M. The earnings-per-share (ttm) stands at -$0.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.16% over the week and 12.77% over the month.
Analysts forecast that Inhibikase Therapeutics Inc. (IKT) will achieve an EPS of -$0.18 for the current quarter, -$0.19 for the next quarter and -$0.69 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.18 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$0.18 a year ago. Earnings per share for the fiscal year are expected to decrease by -69.50%, and 8.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Inhibikase Therapeutics Inc. (IKT) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”